Your browser doesn't support javascript.
loading
Recent advances in cancer therapy-associated oral mucositis.
Abdalla-Aslan, Ragda; Keegan, Rebeca; Zadik, Yehuda; Yarom, Noam; Elad, Sharon.
Afiliação
  • Abdalla-Aslan R; Department of Oral and Maxillofacial Surgery, Rambam Health Care Campus, Haifa, Israel.
  • Keegan R; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Zadik Y; General Dentistry, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York, USA.
  • Yarom N; Department of Oral Medicine, and Saligman Clinics, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel.
  • Elad S; Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel.
Oral Dis ; 2024 Jul 05.
Article em En | MEDLINE | ID: mdl-38968169
ABSTRACT
Oral mucositis (OM) is a common and debilitating toxicity of cancer treatments - chemotherapy, radiotherapy, hematopoietic cell transplant, or combinations. OM is associated with severe oral pain and has negative impacts on patient function and quality of life. Additionally, OM has accompanying systemic complications that may have critical implications. These local and systemic consequences can alter cancer treatment, and add an economic burden. This review covers the clinical presentation and course of OM, differential diagnosis, clinical and economic impacts, pathogenesis, risk factors, assessment measures, biomarkers and prediction of OM, management, research advances in the development of new drugs and treatments, and big data.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oral Dis Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oral Dis Ano de publicação: 2024 Tipo de documento: Article